BioTelemetry, Inc.(NasdaqGS:BEAT) dropped from Russell 2500 Growth-Defensive Index

BioTelemetry, Inc. is a remote medical technology company focused on delivery of health information. The Company is principally engaged in providing remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring, and original equipment manufacturing that serves both healthcare and clinical research customers. The Company operates in two segments: Healthcare and Research. The Healthcare segment is focused on remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders and to monitor the functionality of implantable cardiac devices. It offers cardiologists, electrophysiologists and primary care physicians a full spectrum of solutions, which provides them with a single source of cardiac monitoring services. The Research segment is engaged in centralized core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials.